Identifying therapeutic biomarkers of zoledronic acid by metabolomics

Identifying therapeutic biomarkers of zoledronic acid by metabolomics

Zoledronic acid (ZOL) is a potent antiresorptive agent that increases bone mineral density (BMD) and reduces fracture risk in postmenopausal osteoporosis (PMOP). The anti-osteoporotic effect of ZOL is determined by annual BMD measurement. In most cases, bone turnover markers function as early indica...

Full description

Bibliographic Details
Main Authors: Xiang Li, Zi-Yuan Wang, Na Ren, Zhan-Ying Wei, Wei-Wei Hu, Jie-Mei Gu, Zhen-Lin Zhang, Xiang-Tian Yu, Chun Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Pharmacology
Subjects:
zoledronic acid
osteoporosis
metabolomics
biomarkers
RNA-Seq
ovariectomy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1084453/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1084453/full

Similar Items